<SEC-DOCUMENT>0001213900-24-065899.txt : 20240807
<SEC-HEADER>0001213900-24-065899.hdr.sgml : 20240807
<ACCEPTANCE-DATETIME>20240807062622
ACCESSION NUMBER:		0001213900-24-065899
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20240807
FILED AS OF DATE:		20240807
DATE AS OF CHANGE:		20240807

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immuron Ltd
		CENTRAL INDEX KEY:			0001660046
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38104
		FILM NUMBER:		241181308

	BUSINESS ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
		BUSINESS PHONE:		61 03 9824 5254

	MAIL ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0210776-6k_immuron.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the Month of August 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission File Number: 001-38104</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>IMMURON LIMITED</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Name of Registrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Level 3, 62 Lygon Street, Carlton South,
Victoria, 3053, Australia</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive office)</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 20-F &#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F &#9744;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes &#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
&#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">If &ldquo;Yes&rdquo; is marked, indicate below the file number assigned
to the registrant in connection with Rule 12g3-2(b): 82-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>IMMURON LIMITED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXPLANATORY NOTE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immuron Limited (the &ldquo;Company&rdquo;) published
one announcement (the &ldquo;Public Notices&rdquo;) to the Australian Securities Exchange on August 7, 2024 titled:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">-</TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Immuron CEO to host webinar on MarketOpen Direct Connect&rdquo;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A copy of the Public Notice is attached as an exhibit to this report
on Form 6-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This report on Form 6-K (including the exhibit
hereto) shall not be deemed to be &ldquo;filed&rdquo; for purposes of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange
Act&rdquo;) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B> <BR> <B>Number</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea021077601ex99-1_immuron.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U STYLE="text-decoration: none">Immuron CEO to host webinar on MarketOpen Direct Connect</U></FONT></A></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMMURON LIMITED</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; text-indent: 0pt; width: 60%">&nbsp;</TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt; width: 4%">&nbsp;</TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt; width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 7, 2024</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="padding: 0pt; border-bottom: black 1.5pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Phillip Hains</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phillip Hains</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Secretary</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea021077601ex99-1_immuron.htm
<DESCRIPTION>IMMURON CEO TO HOST WEBINAR ON MARKETOPEN DIRECT CONNECT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Immuron CEO, Steven Lydeamore to host webinar
on MarketOpen Direct Connect</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Melbourne, Australia, August 7, 2024: Immuron
Limited (ASX: IMC; NASDAQ: IMRN) is pleased to invite shareholders to attend an investor webinar on MarketOpen Direct Connect to be held
on</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thursday 8<SUP>th</SUP> August 2024, 11:00am AEST
(9:00am AWST).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer, Steven Lydeamore will
provide an update on additional data analysis of IMM-124E (Travelan<SUP>&reg;</SUP>) Phase 2 trial and next steps.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Following the presentation, attendees will have the opportunity to
ask questions directly to Mr.&nbsp;Lydeamore during a moderated Q &amp; A session.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This webinar can be viewed live via zoom &amp; you register for FREE
via the link below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>https://us06web.zoom.us/webinar/register/WN_QV-yMVvGRQuYq698XMTQxA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A recorded copy of the webinar will be made available following the
event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This release has been authorised by the directors
of Immuron Limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">- - - END - - -</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>COMPANY CONTACT:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Steven Lydeamore</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><B></B> Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt">steve@immuron.com</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><B>About Immuron</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Immuron Limited (ASX:
IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal
antibodies for the treatment of infectious diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Travelan<SUP>&reg;</SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Travelan<SUP>&reg;
</SUP>is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers&rsquo; diarrhea,
<FONT STYLE="background-color: white">a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce</FONT>.
Travelan<SUP>&reg;</SUP> is a highly purified tabletized preparation of hyper immune bovine antibodies and other factors, which when
taken with meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with travelers&rsquo; diarrhea.
In Australia, Travelan<SUP>&reg;</SUP> is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated
to reduce the risk of Travelers&rsquo; Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada,
Travelan<SUP>&reg; </SUP>is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Travelers&rsquo;
Diarrhea. In the U.S., Travelan<SUP>&reg;</SUP> is sold as a dietary supplement for digestive tract protection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: #FEFEFE"><IMG SRC="ex99-1_002.jpg" ALT="" STYLE="height: 81px; width: 680px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right; background-color: #FEFEFE"><IMG SRC="ex99-1_003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><B>Travelers&rsquo;
diarrhea (TD)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">TD is generally defined
as the passage of &ge; 3 unformed stools per 24 hours plus at least one additional symptom (such as nausea, vomiting, abdominal cramps,
fever, blood/mucus in the stools, or fecal urgency) that develop while abroad or within 10 days of returning from any resource-limited
destinations (Leung et al., 2006). Diarrhea continues to be the most frequent health problem among travelers to destinations in lower-
and middle-income regions (Steffen, 2017). Deployed US military personnel, essentially representing a long-term traveller population,
are particularly affected given their population dynamics and the context in which they seek care and treatment (Connor et al., 2012).
Diarrhea is the leading infectious disease threat to the overall health and preparedness of deployed US armed forces, with diarrheagenic
E. coli, Campylobacter spp., and Shigella spp. among the most commonly reported etiologies (Riddle et al., 2006).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>Immuron Platform Technology</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Immuron&rsquo;s proprietary
technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum. Immuron has the capability
of producing highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine IgG can withstand the
acidic environment of the stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal (GI) tract. Bovine
IgG also possesses this unique ability to remain active in the human GI tract delivering its full benefits directly to the bacteria found
there. The underlying nature of Immuron&rsquo;s platform technology enables the development of medicines across a large range of infectious
diseases. The platform can be used to block viruses or bacteria at mucosal surfaces such as the Gastrointestinal tract and neutralize
the toxins they produce.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>IMM-124E (Travelan<SUP>&reg;</SUP>)</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">IMM-124E was developed
using Immuron&rsquo;s platform technology. IMM-124E is produced from the colostrum of birthing cattle that have been immunised during
pregnancy with a vaccine containing the outer antigens of multiple human derived ETEC. A total of 13 ETEC strains are used in the vaccine
to produce high levels of antibodies against selected surface antigens from the most common strains of ETEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">The resultant hyperimmune
colostrum IMM-124E from ETEC vaccinated cows contains significant levels of polyclonal antibodies specific for ETEC antigens LPS, CFA-I
and Flagellin (Sears et al., 2017).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">The antibodies produced
in IMM-124E have been found to have a stronger binding and neutralizing activity (than the antibodies of unvaccinated cattle) against
a wide range of LPS antigens including both the variable O-polysaccharide region and the preserved oligosaccharide core &lsquo;R&rsquo;
region of LPS from the 13 serotypes used in the ETEC vaccine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">IMM-124E is manufactured
into a tablet form referred to as Travelan<SUP>&reg;</SUP>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>IMM-529</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">Immuron is developing IMM-529 as an adjunctive
therapy in combination with standard of care antibiotics for the prevention and/or treatment of recurrent Clostridioides difficile infection
(CDI). IMM-529 antibodies targeting Clostridioides difficile (C. diff) may help to clear CDI infection and promote a quicker re-establishment
of normal gut flora, providing an attractive oral preventative for recurrent CDI.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">Immuron is collaborating with Dr. Dena Lyras
and her team at Monash University, Australia to develop vaccines to produce bovine colostrum-derived antibodies. Dairy cows were immunised
to generate hyperimmune bovine colostrum (HBC) that contains antibodies targeting three essential C. diff virulence components. IMM-529
targets Toxin B (TcB), the spores and the surface layer proteins of the vegetative cells.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">This unique 3-target approach has yielded
promising results in pre-clinical infection and relapse models, including (1) Prevention of primary disease (80% P =0.0052); (2) Protection
of disease recurrence (67%, P &lt;0.01) and (3) Treatment of primary disease (78.6%, P&lt;0.0001; TcB HBC). Importantly IMM-529 antibodies
cross-react with whole cell lysates of many different human strains of C. diff including hypervirulent strains.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">To our knowledge, IMM-529 is, to date, the
only investigational drug that has shown therapeutic potential in all three phases of the disease (Hutton et al., 2017).</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><IMG SRC="ex99-1_002.jpg" ALT="" STYLE="height: 81px; width: 680px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><IMG SRC="ex99-1_003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>References</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Connor P, Porter CK,
Swierczewski B and Riddle MS. Diarrhea during military deployment: current concepts and future directions. Curr Opin Infect Dis. 25(5):
546-54; 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Hutton, M.L., Cunningham,
B.A., Mackin, K.E. et al. Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative.
Sci Rep 7, 3665 (2017). https://doi.org/10.1038/s41598-017-03982-5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Leung AK, Robson WL,
Davies HD. Travelers&rsquo; diarrhea. Adv Ther. Jul-Aug; 23(4): 519-27; 2006</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Otto W, Najnigier B,
Stelmasiak T and Robins-Browne RM. Randomized control trials using a tablet formulation of hyperimmune bovine colostrum to prevent diarrhea
caused by enterotoxigenic Escherichia coli in volunteers Scandinavian Journal of Gastroenterology 46: 862&ndash; 868; 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Riddle MS, Sanders
JW, Putnam SD, and Tribble DR. Incidence, etiology, and impact of diarrhea among long-term travelers&rsquo; (US military and similar populations):
A systematic review. American Journal of Tropical Medicine and Hygiene. 74(5): 891-900; 2006.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Sears KT, Tennant SM,
Reymann MK, Simon R, Konstantopolos N, Blackwelder WC, Barry EM and Pasetti MF. Bioactive Immune Components of Anti-Diarrheagenic Enterotoxigenic
Escherichia coli Hyperimmune Bovine Colostrum products. Clinical and Vaccine Immunology. 24 (8) 1-14; 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Steffen R. Epidemiology
of travelers&rsquo; diarrhea. J Travel Med. 24(suppl_1): S2-S5; 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">For more information
visit: https://www.immuron.com.au/ and https://www.travelan.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Subscribe for Immuron
News: Here</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>FORWARD-LOOKING STATEMENTS:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release may contain &ldquo;forward-looking
statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934,
each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development
programs and any other statements that are not historical facts. Forward-looking statements are based on management&rsquo;s current expectations
and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock
value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth
strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the
results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties
relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key
personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and
intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation
or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in
our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_002.jpg" ALT="" STYLE="height: 81px; width: 680px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !* 0P# 2(  A$! Q$!_\0
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MH/Q7F\]8=;@0QL<>?",%?JO?\*V?$_Q+LM*(M]+5+VX*@F3=^[3(XZ=36?\
M$SPK91Z9_;%E D$R.%F$8P'![X]<UR?@#P];^(-?*W@W6UNGFNF<;^< ?3-:
M1IX><?;6LET(E4Q$)>QO=OJ6?^%H^)/,W[[;']WR>/YYKL_"7Q'@UNY2PU")
M;:[?B-U/R2'T]C77-HVF/9_9&L+8V^,>7Y8QBO#/&&BKX;\3R6]JS"'Y983G
ME0>V?8U-/V&(O!1LRJGM\/:;E='T#6%XF\56/ABS66YS)-)_JH5ZM[^P]ZOZ
M-=M?:)8W3_?E@1V^I'->)_$&ZFOO&UY&Q+")EAC7T  _J37+AJ"J5.66R.G$
MUW3I\T=V7[SXJ:]<2DVRV]M'V4)N/YFM+0OBO=+<+%K4"/"QP9H5PR^Y'>NY
M\-^%=-T/2X8EMHI+@H#+,Z LS=^O;VKEOB9X7L5T<ZQ:6Z0SQ.HE\M<!U)QD
MCU!QS73&IAYR]GR:=SGE3Q$(^TY_D:'B?XD6.D!8--"7MRRAMP;Y$!Z9/<^U
M<2?BCXD,F_?; ?W?)X_GFJ7@/P_#X@\0K#= M;0H99%!QNQP!^9_2O;O[&TS
M[']D_L^V^SXQY?E#&*)^PP[Y''F8H>WQ"YU+E1Q_A3XDPZQ<I8ZG$EM<N<1R
M*?D<^G/0UWU> >-M$C\.>)W@M"RP.HFB&>4!SQGV(->V>';Y]2\.Z?>2?ZR6
M!6;ZXYK'%481C&I3V9MA:LY.5.INCB-7^(VH6/BJ72X;2W,,<XAW-DL><$UZ
M57@7B/\ Y*+=?]?H_P#0A7OM+%4XPC#E6Z_R'A:DIRGS/9_YA7GGBSX@WOA_
MQ!+IT-I!)&BJP9R<\C->AUX9\3/^1WG_ .N<?_H-+!TXSJ6DKZ#QE24*=XNV
MI[9:3FXL8+@@ R1JY [9&:\[T[XG32^(197\%M!:!W#S9.5"@G^@KO\ 2_\
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M*OOJG_H0KC/A!_R%M2_ZX+_Z%7:?$/\ Y$F^_P" ?^A"N+^$'_(4U+_K@O\
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M4H-6TNWOK=@T<R!N.Q[CZ@TL8KTZ<EM;_(,([5*D7O?_ #+E>&?$S_D=Y_\
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98Y&&&D8EG/XFM:BBLY2<G=LTC%15DC__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !O Z0# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_4?ZQO\
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MZ?\ UZ +%%1))O)&.V?U'N?6G.^P ^^/T/N/2@!]%1))O)&.V?U'N?6G.^P
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M^)>(/[4QE&3M:I_95+%99'&U(N_[B..PO,I7]K:DXUOZ+O&__!8SX5V DC\
M?#/QKXGFC1HUN=?O=*\-Z?,X!VE)=.NO%*1@D!@ES]CN-F\GRC&8V^.?&O\
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M33RW+F:>::>9C\\LQ\QV[G,V26).#COUSQBH:*P-6_*W]??\KA1110(****
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M7IW;1]U@Z$<)A:6'V]E35-_-."_&:7E^!_&_\/3M_P"#@"0D'C]H?XB$CZ>
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MBGE%*O6EF&)E2DU"6)J1K8E1>D75Y$VZ=1GC8#PPXARW*.#,-CLRCQ!FU#Q
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M_GA@\SR#((SBXJ&5\%U,5F<+M.^#I5:E2-3$)1M%-)<CJR?PH_?CQ+_P6_\
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MXO\ BAV;[/%I=G&W :*R\R?']TSGEE[D=R%;C&*P+CX@>,;DL?[?O("V0RP
M6RE/[N[J1G!VG@XS_#7$T4%*C"+4E!)K9VV\[N[6^Z+]YJNH:B2+Z^N[L[Q)
M_I%QYJ[@"H8+_>"L0&[ L.]4***"PHHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH _U#1_K&_W(_P#T*2H[@X0,1PK9) 9G7*LH,:*C
MEW)8(% R0QQDX5I!_K&_W(__ $*2E;IUQSUY]_2O\-*EE"3<_9JVL[I<NJUN
M]%T6O<_Z$5>ZMN? _P"TK^P/\)/VATO;\V]GX:\0ZEF?67_LR6^T769_L\Z0
MW6H:+;ZAIDMOJI,VQ-8@N&N8;5KJ 6TK73R#\?O&W_!"^5]1631_#OA74K5M
MT:W7AWQ==:1.R-ER&L?%.EBZ@DP@+^3K4\8 94AE4B6+^G8X[N<>X/\ C3<J
MI]<\8(Z^XY/YD<=Z]S+.*>(\KA&&7YK*.%7Q1WO&SO:2=GTMN<&)P."Q$N>O
M!^V7PM-WN]-O1O=_\'^?SX)_\$7O#7@VZM-2\1CPGX;D@* MH\%_XLU_+20R
M?O8+GR]*-^Z1MG4+5I);1/,DC5HS)7[<_"CX4>!?@_X>C\+>!-%BTJR14DOK
MD[Y[_5[M=R?;=3U&4>9?7.-P )VVRL8T2-7 /I1/)&>.WH,^WM]*5&7>5')"
MDD^V1^74=?TY%<>/SC,<VJ\^,S"5=\W-*GI[RULGK?S5D[-%87!8; K]U%J5
M5VU=]]=M4MNY-1117$=@4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5'*
M5 92PW#@$#'!YY__ %U)44PRJ_.4PV<@D9PK9&1VQR>G3.>*F6D6^1U-/@6\
MM5HK_?\ )B>S]_V?]]_9\^GIOU&A!V0CZD<?B1_*FS !1A4SN .26/0YX"MS
MP.WMFN;UKQAX7\.KNU_Q!HND ';NU35K&P0$J[8,E]<6Z[BJLP7);:K$*RAL
M>/Z_^U-^S?X?4#6_C[\%M&83K"RZM\3_  38D/LD?R_+N]9_UF(V^0("55_F
MP"#I2PF/K\JPV68JJY-<M/"X7%XJO-]%2P^#H5J]6;M>,*493:4G:T9,\W%9
MQE> A4GC<UPF'A23E4J8K%87"8>FDU>5;$8K$8;#TH:J\ZV(I03<4YIRBI>^
M#*\[$'&,A6'?I_J.G]:6,G<2Q49!Y^9AU!Z>5'SQU!]L8)KXJU?_ (*#?L6Z
M*SF__:9^$;;259=(\16WB!@<,V47P_#JA=<+C>J;-Q5-^YD#>3ZQ_P %:/V!
M=!=P?CTNKW /EF#1?AY\4;O(Y8NEW!X+-FZAE"X$X!+J0<*37TN&X#\0,=&+
MPW!'&%:G5LXN/"G$=+F4M5;$5L+&C23_ )ZLH15[-1YD?*XOQ0\.L%&<\9QM
MPA14$Y2F^*N',1*"32;6%PW$&)Q-9Z_PZ.&KS=[JG:,G'],SN(Q\I'T/?Z?X
MFFD$#HOX':?S(.?IUK\=]8_X+<?L8:6\K6,WQ2\2QIN"?V/X(^S&0<_O$/B3
M6]#8CC;L\E)B64A-JN1Y-KG_  7H_9W1#_PC7PB^-VID/@'5[?PIHD;C:Y#*
M]MXRU:=5SM'-J58$L64HJ/\ 2X7P0\7L8G+#^'7%-."C?VV-HPP.$@M-:V,Q
MN(AA:$=5>I7G"";2<KRBG\MCOI!^". A.6(\1.&JM2,7:C@Y5L=BIM-+EH83
M!TIXFM4>K4**E-Q4VE:$C]WQ,!\N1SZOD_EM&1GZD4&8#[NQSW ?D>_.T?J>
MO2OYP-5_X+^VJ2.N@_LRW%[%R(Y=6^,)L)]H!P\UEIG@'5I%P0,JUX(\G!F#
M;,^2>(/^"]WQGO=XT#X&?"_155B\)UK6_$7B3;M5@!-Y&K>&3@;@QF$",-NS
MRP7#+]#@OHU^-&,]_P#U4PF$BFOWF.XLX5IT$FK\U2>'QM:I&FMG*/O)N.EG
M)KY'&?2P\"\(GS<88J;C%OEPO"G$\JSLTK47B,)3HN>NU3W+<VK?*?U.Y#+R
M #[E3W_K^/'/8"JYPC98K&,8#A5P3G[H!W#'!.0.V ?7^0G6/^"XW[9&I"1;
M#2O@MX>7<3'+X>\$ZW>R1KAU"M/K/C+5[5NJL2+1I-Z*%D$?F))XUK?_  5_
M_;PU-W>/XZ6FB1EB?LFF^ OADD<:X8$*^L>#A<*!G@C5+B0'!$,@S+#]3AOH
MC>*^*C&=:KP9@Y.UW4XJ6,]@W]IT<!2K5ZR2NN7#QJ3=[J-E)KY?&?32\'\/
M&:P>#XRSAP3<:M+AE82G)W5O]HQU2GAJ2:;]^NXP6SLY03_M=4YY63</8Q*3
MUXX&>WT_(U'-(8D#2),R[L#9ME(;!QE0A('!&<8!P#UP?X5-5_X*;?MIZNS&
M\_:?\9PLS;F73K_PQH8X!4[(]'T:P2/ECE8YFY((B;&]/--9_;L_:AUI6CU+
M]J3XVS*6WO%'\4O%L%JWR.F%@MKRPLQP[ >7,S8)Q$5W,GT6'^AKQO)P^L<:
M<(T9MJ[P^%XGQ%:#ZNE0EA52K26J4:DHQDKNZLCYG$_3DX(BI/#<&<65&DW!
M8O$<.X7"2?15ZV'>,Q%*GO>='#8BHI<B]FU*3A_?<;N$A07>+G_EIA ,]2W[
MG@>O3'<Y&*XKQ%\3/ 'A%R/$GCOPCH93/F?VYXHT_3DB7#,7D%W<0*-H4Y!.
M_ 8XV@D?Y[_B'X[^+_$H8>)?BAXZU]GD\R0ZQXGUW7#,VUU)V:KJ]];JY$C
M3)"LRJ61)%CDE1^!/C#2-QP]T[,=S!CF5B?^6C%0WR]N>,L.<]?I\)]#"NO>
MS+Q%E4BDN:E@>$YT,2WI=4L1F6)CA(/7W98B5.%DTY)N"?RF/^G973:R?PYH
MR;34*F+XHQ%:A'71U<+@N&Z.(K0LM:=*O2FVX-248R4O[]M=_;<_9)\/!O[8
M_:7^"4,T;[9;>Q^(VB:G=*0K,5;3M*U"[NE.$.9# 4#@1D[Y$5O$/$G_  56
M_8/T(2++\>+74I8VP8=#\&?$#6EDP&),=S#X-.FN#C&];\\L  58NO\ #E)X
MUTE!DPW+\X </MSS@C]WU&./;..:JOX[M-ORV3R+D;0\DD7.!\P8H 3@D!>N
M#GM@?4X+Z''!$(1_M+C+B^JT[SY7PK@:<H:>ZZF'K8FO171U:#E4U7+:[/B\
M?]-[Q(Q,Y?4?#_A*@I74:\UQ-C)4F_\ EXL/B%1PU=K;V=9>R=V]XQO_ &4Z
M_P#\%M?V.-&;;IEC\7O%FTX670_!&FV,3X5CYID\0>)-"<1$@*5,1FS(K"(J
MKE/"_$O_  7F^%H$T?A?X%?$;450EK:76_$WAKP^DF P F^PQ:[+!DE>8_MI
M4;B(6QN7^4&;QVX4;+"-4R,-),TH)(Z;<'#8R=W/ QWJB?&VK2.5MX+2/Y2V
MX$@[<J-OS;< D],9^7\:^QP'T5/!C"4Y1JY?Q9G-:22IXBOQ5"KAH25O?E0H
M4*4ZD'JG#GE=\K37([_'9A]+OQPQDI1P^9\+Y#2:=X83AJCA\6E=.]'%8^&/
MPM&JFDE.MA:L.5SBZ;<XRA_2IKO_  7H^(5PI'AG]G;PMIN&*)+KGC_Q'XHC
M((;YYVL_!/AC8,X8QK"RCA1=DX#>-:S_ ,%O/VM=1>0:9X6^!^@0,V8VL?!7
MB;4IPN& C:\U#QZENY.[<P_LI7+(I!"!D?\  9_%_B L09((>^]$24GL%P6Q
MCOGJ" .<YJ%_%>NL-K7S8SG]W"(S_P!](22.>1T)^E?78'Z/7@UE]*-1<&4\
M54H+FC',7BLPH5;-*V*PSQ45B8.[<H2IZR4&U:.OQ.8_2(\><SYW/Q%Q5.C-
M-2CA*O#&#Q"BVK^PQ&$X5PN+H25E:5#%49I<T>?EE)2_:W4_^"OG[<VH.SVG
MQ%\.^'5)+I_9'P_\#R(I (\H)K^CWC(A!W;Q?SSAD4+&ZM(R>.>)?^"CW[;O
MBR.9-7_:)\<0K<-A8="BT#P\L;D%0\!\.VNA_9&VLRB5+R15W<V[MMEA_*Y_
M$>NN,"^NSDY'ER2HW?\ BW@$>H_3BH&UO79%PU[?LHZ[KIL#KZEAD9)Z#N<]
MC]#A/#'PYP5_J?AEPERRLI?5>%8X;$S4;M*E7J2JPHSZJ;@XV4UKS67RV)\5
M/%?,8NGC/$KBOW[P:Q/$E7%82SU?ML-"$%6INVL-/>Y7=<I]P^(/VAOCKXH&
M/$WQF^+6O (4E76?B+XSU?S-Q.Y!]IU:^TJ-&R1Y<$"7'9)5B\U7\DFU22>>
M6YN[XF5PQDDO;S4)+MV8@LSSW?[I@<9('SD[2,*&%?,T]U/(29KB>4[N5EF,
MH!Y^;:>C+R ?0D<YXA(&-V,$D#.<]OTZ=/:OM,NP.595A_JN69?2R.E)6C@*
M-.E2IR_NJ-*G3@MFW:*NXMZGQ.8U\=F=9ULVQDLWQ3]Y8R7,Y1EUFW*]WJ[M
M[WW/I"37])B)$VH6J$9!)N!-DC_9' XZ'.1T[FL^3QAH:%O^)G"X'01Q"4^F
M=O9<Y&X\Y('<5\^T5V'G_58]$[_X8_Y'NW_"PM$C8_Z3/( ,;8;+#YSGYCT*
MXZX_BQSUQ4D^)&DH2T-A>RN>-SA;88(SGS 3DD@?)CD9;JM>*44%?5H=8R?G
MI_\ (GK3_$[D^5I9QSC[1>-LP?3(X;J!C@#<.V!1E^)>JM_J;&RB]Y&-T"/3
M8<8SPV_MC'?%>9T4#C0A!\R@TUJF[Z>?X]=-3O3\1-?E9E2*Q4X))CM/FP,<
MD#G&2.?7&<54?QUXC;*G4%A.<E8+?RF^A;DE?49Y(4]CCC:*#0Z)_%/B.4D_
MVK>#/)*2&)L$ <MSD#/W<>A[5FSZMJ<P_?7]W*V<E9[CS%Z'Y@F3AN<;L< D
M9YK/HH 0L68LS[F(Y]N?7 ']?:EHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH _T^! -SA$"-A2618@V0SC/^I _P X&<C#O+D7# #=@C>Q#%E.#RL<
M.X$D#K\HQV) '\+\/_!9O_@HG OVA?C?83"4[RM]\*?A? L8F9IE'E1^#+61
MC-"\$@D:1T/WBK,^X:B_\%J_^"AB6XGN/BOH$J>8(5=_A9\.6A+%2P*JV@QI
MN*ID$#(7<!D$X_S/E]$;Q.<XU(9CP;*G5HJ24<QQMW>UO>?"SD[[<LI3CH_<
MT5O]3X_3/\*.55:V5<90E+$/":9?AJ[3AS>][!<2ISNH6<;7EHTVD?W&'SAU
M*#ZI-_\ &:3=(.I4CV67/_HAOY?C7\.\'_!;K_@H!"Y9OB;X2N 5*[)_A3\/
M0@.0=P^R:?:2;A@@;I&3#-E"VUENI_P7%_;^0DCQYX$GXQLD^%/A5E'(^8"V
M(?(QC)^3!.>=M*/T1?%"+3CB>$)23O&/]KU\/=]O;5N&L+2I=?>GB*,5:W.G
M)*6W_$YOA(W;ZGQE33WJ2X7IVCYNW$VW3;JC^WS>W^1-_P#(U&]_I^$O];8U
M_$2/^"Y7[?PY/C'X=L/1_A/H>/J,-G/],U)'_P %S?V^PQ+>+/ALXQT_X57H
ML?.1SN+\^F/?/:M7]$KQ8[\'OTXPPE_N]B5_Q.5X0_S<6_\ B+Q_^B0_MRWO
M]?PE_I;"C>W^1-_\C5_$H/\ @NA^WP#_ ,C+\-']G^&.B ?7B0<_XFG?\/T?
MV^/^AA^&'_ALM%_^.TO^)2_%G_JD?_$NPO\ \I!?3)\(OYN+/_$8C^O$I_;3
MO;_(E_\ D:DW/ZG_ +YD_P#D6OXEC_P70_;X(_Y&/X9I[I\,=%)^AS*>/Z@5
M%)_P7._;Z*@+XJ^&Z'/7_A5NB2<8/&T/QZY]L=Z/^)2_%G_JD/GQ?A4OO]CH
M#^F3X1?S<6_^(Q&_X<2V/[;MS^I_[YD_^1:4/(.A!/\ M"4#]+8'/XU_$2?^
M"Y7[?SC"^,/ARIZYC^%'AT-CT/VI_+QSV^?(&/EW4P_\%Q?^"@!X;QSX A']
MY?A3X/R3_=_U@X/7\*3^B3XL--2K<'4D]ZCXPH24%_,XT\)7F^UHT:CU^%J[
MC+^F5X1+51XOJ6^PN%XWEY+_ (R;^K']O8DF_P!C\#.?_:(I2)9/E901UQA_
MI_RUB"]^WS>G&:_B ;_@N%^W\00/B%X('O%\*/!VX>Y_=7A"^I\I><?./NOG
M7/\ P6V_X*$2IBW^*WAB%]V2MI\*? L<JK@Y+-/H+JT><;@#G=M/0&H7T1/%
M&3Y99MP6XO1I<2UJ]U_UY7#<W4_PJ$K[V]W29?3-\)>5M8#C.3Z1_P!7:.';
M>FGMI\2VIW_F>FEOM(_N.\EO[G''&(NWT2I(T\LDN  00"?+ZD@X^50>QZ_X
M5_"M+_P6E_X*-2 ^7\;].A.2<6WPK^&18#YNOG^$KQ=O(S^[4[MOS@;E;/D_
MX+*?\%)9SM7]H(\'=Y5M\)_@YYH XRQNOAVZ&/G!P-Q8KVW5:^B!XF)IK,N#
M$UJF\=CVD_3#\(.N_P#N$G/LK<QE_P 3F^%EKQRGC-R6JC]5R]7_ /!W$RIK
M?_EY:'FW8_N]+Q]BGXBD+(<#"'GGD#\?F7'X=?PS7\'Y_P""PW_!260%6_:#
MU"(8SN'PF^"G)]!]G^&C,I().YAM&.6SMK#O?^"MG_!1BX^:X_:0\2JI8+F'
MP-\+K1<@-]U=-^']C.IP3C?(\0ZM&SB-H^JA]$#Q*G)1KYYP9AX-V=15.*ZB
M2UUO_JO@TK66]>FM?C6TL:WTT_#2%.3AD'&-1I:1='AJ";TTE?B#%-)ZZJA6
MZ>Y]J/\ >WE1R%0GTS%_5:!M;LBGKD>4WX8 _7%?P!W/_!4S_@H+<?,W[3?Q
M"B+$9,%AX3@4YSD+':^& \?'(8C8",'G:*Q9O^"EO[>%Z62]_:A^+H7&X>3K
M-I9(&Z91=-T:UN%(5FQOD,/JC.(RO>OH;\=7][C#@Y+JU'BINW9)8:S^[YGG
M/Z;7 "7-3X0XOJS^S2YN%X\S71MU;I-7=]=ME<_T%]B_WE_[XC_PICE8@&)4
MY( ^0'D@G/R(2.G4C'OTK_/,N_\ @H'^VG>;O/\ VJ/CTO5L6OQ-\2V0SR,J
MFF7-E.O7'S,8AGE"_ELO,W/[;?[7]V2)_P!J3]I6[4Y)AD^-_P 2)8 >0'%K
M'KX,;#E?,V@*'*YRX!TC]#;C&<E&KQKP?3IR=IU)87B:M&$=;MTJN'C2J6LO
M=G)1;:;>B,G]-[@VUX\ \6J72^-X6H)/O[9S:IWVYM;;6]X_T5Q+N&4&??RW
M(/TQ&/Y^M,>8QX,L?RD[00A.&P2,_(<# /.../6O\XFY_:G_ &EK\M]N^/GQ
MVO<L69;GXN?$.XRP!&YH[K7Q&" Q7>OSC<0,*S&N7O\ XY?&34%Q>?%CXH3$
MMEFO/B7XKE#G###)>:G?1$D'/$2R !@'5=X?TJ7T+,TYH.?B/PVE?WGA.&<3
M5KQT=_81ECL(IROLI5J.G-[R:Y9<%?Z;^1:^P\/L^:2O_M/%'#\:-NCK?5L)
MBJRAW]C1JSORVBUS./\ I-B[ASPZ)GN^U0#S@D^6N!GU_.JMQJ=C NZXO[2W
M7=@O+<PP+D@G;YDV$/ )VCYB%)' :O\ ,^O/&GC34-QOO%OB.\\S(9[O7KZ^
MW,<_>>Y.SIGYAA^H!(+"L7[?=$8EO#-(3N+R3>8Y]R"N>_WCQT&.<UZ%/Z%F
M*4X.IXDTU34ESM<&5+<NM]5Q-B9+6WPX>L_^G;5W'R:OTXJ<?]W\.KW^%/BZ
M*3_O-0X6MWTN?Z8%UXT\(66?M7C'PQ;8.";KQ#ID !P?E)=P,\,<9!P#Z&N;
MOOC)\)]/3-[\4/AU;G>%)G\;>'8"I(<\M/>QC@ G;U[XP#7^;%]LG?CS0/;"
MC\>%_P *CDN)@/OJ_/0JA'0\_, ,]N#GD^]>I'Z&&"YTI^)&):TO]4X.J2Q&
MV]&,IZS[*4MN9WNCDK?3BQKI35+PZPT:O+^[^M<68MX92NK.LL-P[AZ[A;FO
M[*M2G?EM-+F4O]'RY_:5_9]L1F\^.'P<M<$J?M'Q,\#VY4X)P3-JJ#. 3C.<
M GH#7/W/[8W[)NG'?J/[3'[/=GSMQ<_&+X=QMO(9MAVZT6W$(QQZ \Y'/^<Z
M;B5N"(QW^Y!_@:3)D^5WC0#D'8@YZ8S&N[H3UX_'%;2^AAE<4V_$/BJHDKN'
M^I^'PO.KKW?K&,KPPU'?XZ\XTE:S?-*%_-?TX.(K>[P%PM3GK:;XDXGKJ/:]
M%8=2J6_E3UWZ,_T.+W]OK]BK3I':X_:E^!D@4$%;+XC^']2.>.1]EO[N)NA&
M8TW<X#X8JW":Q_P4Y_8)L<_:?VEOA[*(V/R:<NN:N<A6^9?[,T74D9< @ND0
MY**)1N"O_ (%V_=N4'T\S_XFB1G=0#-YH!SM ;C@C=]T#OCKGGI7J4/H<\$J
MG?%\7\8SJ*.KA#ACWWHM*>'I9A7M_=I8?$S5K*G)*4H>9B/IM\>U'*-#A3@^
MC3E=<[?%-116GO-^WPDGLEI6I/7XUM+^[K4/^"N__!.VPRDO[04-PZM@KIWP
MZ^*UV2P#?\M8/ $<# \\^>1SG'\0XK4O^"T_[ 5@2UA\0_%^IL'V%].^&WBJ
MV9TVDGY]2TS26*$A<J[YR5/ED LG\.H+#O(!W()7I[Y[>O&,Y^KS*6&/,EZY
M^9RP_(8YY//IGUKU<-]$#PUHP<L5G/&N+I1]Z<)5Z> O'16^L0X7PM&@Y-I^
MTJ5H)6MS)S2EXV(^FCXIM2^J9/P9AVU:-58'/\3[-_S>PQ?$5:E5TNG"M2J0
M?-=P;C%Q_M0U+_@NY^Q-9_ZBQ^,FMD,%"Z?X+\.1$C#'S1_:_BG3"%RH7)?S
M,LN$(W,G :Q_P7__ &5H%QI'PL^.<[K(-LUW9?#W2HI$VO\ *98?'M]+DMM8
M1F J54L3N10W\=FXCI*X_%O\:<""?F,DO4[02"#G[V2&SW!X')ZU[&&^B=X.
MP][V'%6,:2Y</C.+I?5JKWY:KP.$CBE!J]_J]ZEU&RMS6\/$_2^\9\1%\F)X
M:P4K-K%8/A/#O$46_MTGBZTJ'-'6*]L^2TY7=^4_K'U'_@X4^%D,DC:1\!O&
M&H '"C5O'^B::67&?F6P\.:VR8;:#^]:,9;+[@ WG6K?\'%)RR:3^R_IJ*#\
MMSJ'QHOKIRH5L![/1?AE+<IDD$O*T=NN-CRK(\0;^7W=!G_5O]"X_HHI0\>?
MEC4'_IJ2RX]AZ].?3->Q2^C'X.45;_4FI7ELH+BSBC$SGJM(T,7&%"JY6?N5
M9QA9-MIJ)X>)^E-XX8F+C_KK5H*2:=3 \,\)X3$P725&O+#8Q4JD;:5'AL1=
M.:]F^;FA_1[J'_!PQ\4I-YTGX*_#&R#,-D-YKWCO7)(QSS*MJNE2E<@;G:VM
MT&0NY'9!7F^K_P#!P#^U'=;QI_@[]GZQA+YC0>"OB+J=]'D, 6>Y^*T,6U<@
M,YTM3NV@X5F1OP+\W!QY=N>.OEDCZ<]_P_&CSB>D</\ P&/!_/'3V^GI7J4?
MH^>#6&LY>&L5RN[>,J8S%X33I7PL,;'V])=:?5\K:?*T_%K_ $AO&W%1G&7B
M3Q<XSARM.7#>$5FU?]_@^&,+6H[?'2Q%&:VYTI-2_:75/^"YW[:-XSO9ZW\/
MM#5B0HT;X=Q,$X.%5-7BUD@ X;,ETX!51NQG/G&I?\%E_P!O?5"X7XYWUG"Q
MW+;:3\-?A1$4/0%99/#K7ZH Y!W$@-M)&X*3^3^]VS^Z0Y&#^[SQZ4$D?-)&
MRJ>!L41Y//<J1ZG&,GKG KZ##^$WA;AW!X;PXX+I*#3C7?!]"3AR_:7URK]5
MT=E?$+D=[RO)QO\ .8CQ?\5<7S1Q7B)QC74TTZ2XJQ-*,[V?+?!5,'B+:7_=
M8FA+16FES*7Z*ZI_P5&_;BU9I&NOVC?BQ&'R2FG7UCH:Y.03''HUEH:Q#GI'
M=R@'&VV;'FP^8ZG^WE^UIK$CM?\ [1/[1%R"2YB?XU>/[:SS@KN6Q.OG3T8*
MS*#$!*%9E3]VSBOCCY#_  S$=OF!_P#9*:1@959![GICKV _GTKWX<$\'P@Z
M4.#N$51E&TZE#A'A+#XF"WO0Q.'IU<31FG&-JE"$II.222E-KP<3QQQEB4WB
MN*^*:[5W[+%<5<48S#5/[M?#8OB3$X6O3?6EB,-6I<T8MTVX0<?H_4?VJ/CQ
MJ3$ZG\6/BK?E_O-=_$SQ7=2L<$9D>[U2^C<%2P(6!')(VRHH='X'4OBWXSU3
MS#J>NZYJ)D8[SJ&KWVIR=,$N;HE 3G&\#> 2%^5FKRP*[= 3_GK_ /7H*,HR
M00.G->WA,IRW+X1A@,JIX:G"W+*$(05.RLFHQC!*RTNHK?8^=Q69X_'.3QF/
ME7<KWA)R?/KMM9:]WK;<Z;_A+M05BT<-NP;)+N/WA).2#TX]>O..3UILGB[5
M'4 +;18.=QB$F>"-NTYQG.<^V.]<S17<<'R7]?,Z#_A*=7;A;B%#US%:J&QZ
M'Y>G3/N!3)/$FLNH#7L@ .?DA\LYP1RP R.3QZX/:L*B@#4?7-5<8-_<]<_Z
MPQ=C_%GGK]WOU[5"^K:DXPU]=$ Y_P"/SOR/7WJC10!9-_>,,275TXZ@?:!+
MSZ[3G'!//;..]1/=2,,/),XSG$F" <'D8QSC(^A-1T4 'F;^,>_^>3ZT444
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M &OACGO).UY1X:UA:H[)R:2LO9*RM_"%_P .>/\ @I#_ -&\WO\ X=;X&_\
MSRJ/^'/'_!2'_HWF]_\ #K? W_YY5?W@^4GI^@_PH\I/3]!_A6?_ !-OXI_]
M"C@[_P ).+O_ *,3+_B3;PO_ .A[QC_X6<,?_0R?P??\.>/^"D/_ $;S>_\
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MO_Z'O&/_ (6<,?\ T,G\'W_#GC_@I#_T;S>_^'6^!O\ \\JC_ASQ_P %(?\
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M'^%'_$V_BG_T*.#O_"3B[_Z,0_XDV\+_ /H>\8_^%G#'_P!#)_!]_P .>/\
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ME)Z?H/\ "CRD]/T'^%'_ !-OXI_]"C@[_P ).+O_ *,0_P")-O"__H>\8_\
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M'_HWF]_\.M\#?_GE5_>#Y2>GZ#_"CRD]/T'^%'_$V_BG_P!"C@[_ ,).+O\
MZ,0_XDV\+_\ H>\8_P#A9PQ_]#)_!]_PYX_X*0_]&\WO_AUO@;_\\JC_ (<\
M?\%(?^C>;W_PZWP-_P#GE5_>#Y2>GZ#_  H\I/3]!_A1_P 3;^*?_0HX._\
M"3B[_P"C$/\ B3;PO_Z'O&/_ (6<,?\ T,G\'W_#GC_@I#_T;S>_^'6^!O\
M\\JC_ASQ_P %(?\ HWF]_P##K? W_P">57]X/E)Z?H/\*/*3T_0?X4?\3;^*
M?_0HX._\).+O_HQ#_B3;PO\ ^A[QC_X6<,?_ $,G\'W_  YX_P""D/\ T;S>
M_P#AUO@;_P#/*H_X<\?\%(?^C>;W_P .M\#?_GE5_>#Y2>GZ#_"CRD]/T'^%
M'_$V_BG_ -"C@[_PDXN_^C$/^)-O"_\ Z'O&/_A9PQ_]#)_!]_PYX_X*0_\
M1O-[_P"'6^!O_P \JC_ASQ_P4A_Z-YO?_#K? W_YY5?W@^4GI^@_PH\I/3]!
M_A1_Q-OXI_\ 0HX._P#"3B[_ .C$/^)-O"__ *'O&/\ X6<,?_0R?P??\.>/
M^"D/_1O-[_X=;X&__/*H_P"'/'_!2'_HWF]_\.M\#?\ YY5?W@^4GI^@_P *
M/*3T_0?X4?\ $V_BG_T*.#O_  DXN_\ HQ#_ (DV\+_^A[QC_P"%G#'_ -#)
M_!]_PYX_X*0_]&\WO_AUO@;_ //*H_X<\?\ !2'_ *-YO?\ PZWP-_\ GE5_
M>#Y2>GZ#_"CRD]/T'^%'_$V_BG_T*.#O_"3B[_Z,0_XDV\+_ /H>\8_^%G#'
M_P!#)_!]_P .>/\ @I#_ -&\WO\ X=;X&_\ SRJ/^'/'_!2'_HWF]_\ #K?
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M ,\JC_ASQ_P4A_Z-YO?_  ZWP-_^>57]X/E)Z?H/\*/*3T_0?X4?\3;^*?\
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M@^4GI^@_PH\I/3]!_A1_Q-OXI_\ 0HX._P#"3B[_ .C$/^)-O"__ *'O&/\
MX6<,?_0R?P??\.>/^"D/_1O-[_X=;X&__/*H_P"'/'_!2'_HWF]_\.M\#?\
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MX<\?\%(?^C>;W_PZWP-_^>57]X/E)Z?H/\*/*3T_0?X4?\3;^*?_ $*.#O\
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M*.#O_"3B[_Z,0_XDV\+_ /H>\8_^%G#'_P!#)_!]_P .>/\ @I#_ -&\WO\
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M4GI^@_PH\I/3]!_A1_Q-OXI_]"C@[_PDXN_^C$/^)-O"_P#Z'O&/_A9PQ_\
M0R?P??\ #GC_ (*0_P#1O-[_ .'6^!O_ ,\JC_ASQ_P4A_Z-YO?_  ZWP-_^
M>57]X/E)Z?H/\*/*3T_0?X4?\3;^*?\ T*.#O_"3B[_Z,0_XDV\+_P#H>\8_
M^%G#'_T,G\'W_#GC_@I#_P!&\WO_ (=;X&__ #RJ/^'/'_!2'_HWF]_\.M\#
M?_GE5_>#Y2>GZ#_"CRD]/T'^%'_$V_BG_P!"C@[_ ,).+O\ Z,0_XDV\+_\
MH>\8_P#A9PQ_]#)_!]_PYX_X*0_]&\WO_AUO@;_\\JC_ (<\?\%(?^C>;W_P
MZWP-_P#GE5_>#Y2>GZ#_  H\I/3]!_A1_P 3;^*?_0HX._\ "3B[_P"C$/\
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&'_T,G__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex99-1_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  R +<# 2(  A$! Q$!_\0
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M_&FU5QD"2(X/L@(KU9E#*58 @C!![TY2C1C%**=U=W%&,JTI-R:L[*QY3/\
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M)J-F:]%%%9F@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
*4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
